Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma
- PMID: 9625824
- DOI: 10.3892/or.5.4.817
Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma
Abstract
Overexpression and amplification of Met/HGF receptor has been detected in gastric cancer tissues and cell lines. In this study hepatocyte growth factor (HGF) and Met/HGF receptors were localized in 32 gastric cancer and adjacent normal gastric tissues by the avidin-biotin-peroxidase complex technique. HGF (87.5%) and Met/HGF receptors (68.8%) were demonstrated in gastric cancer tissues. A high positive rate of HGF (87.0%) and Met/ HGF receptors (82.6%) presented in intestinal type gastric cancer. HGF immunoreactivity in gastric cancer tissues was a significant and powerful prognostic indicator (relative risk 15.9; p=0.01). These data suggest that HGF and Met/HGF receptors are involved in the morphogenesis of intestinal type gastric cancer. HGF may have other mechanism that favor gastric cancer spread and independently affect survival.
Similar articles
-
Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis.Lung Cancer. 2012 Feb;75(2):181-8. doi: 10.1016/j.lungcan.2011.07.008. Epub 2011 Aug 27. Lung Cancer. 2012. PMID: 21872356
-
Expression of hepatocyte growth factor and c-met receptor in gastric mucosa during gastric ulcer healing.Scand J Gastroenterol. 2000 Jan;35(1):23-31. doi: 10.1080/003655200750024489. Scand J Gastroenterol. 2000. PMID: 10672830
-
Expression of ezrin, HGF and c-met and its clinicopathological significance in the benign and malignant lesions of the gallbladder.Hepatogastroenterology. 2012 Sep;59(118):1769-75. doi: 10.5754/hge11744. Hepatogastroenterology. 2012. PMID: 22172411
-
[Expression of hepatocyte growth factor and its receptor, C-Met in human digestive tissues and different gastric and colonic cancer cell lines].Gastroenterol Clin Biol. 1996;20(5):438-45. Gastroenterol Clin Biol. 1996. PMID: 8761141 French.
-
Current advances of targeting HGF/c-Met pathway in gastric cancer.Ann Transl Med. 2018 Jun;6(12):247. doi: 10.21037/atm.2018.04.42. Ann Transl Med. 2018. PMID: 30069449 Free PMC article. Review.
Cited by
-
Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the MET Gene: Doublet Treatment versus Single Agent Treatment.Int J Mol Sci. 2024 Feb 1;25(3):1769. doi: 10.3390/ijms25031769. Int J Mol Sci. 2024. PMID: 38339049 Free PMC article.
-
Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?Oncotarget. 2017 Aug 1;8(59):100863-100898. doi: 10.18632/oncotarget.19809. eCollection 2017 Nov 21. Oncotarget. 2017. PMID: 29246028 Free PMC article. Review.
-
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy.Oncotarget. 2015 Sep 22;6(28):24750-79. doi: 10.18632/oncotarget.4990. Oncotarget. 2015. PMID: 26267324 Free PMC article. Review.
-
Met receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodia.J Cell Sci. 2012 Jun 15;125(Pt 12):2940-53. doi: 10.1242/jcs.100834. Epub 2012 Feb 24. J Cell Sci. 2012. PMID: 22366451 Free PMC article.
-
MET: a promising anticancer therapeutic target.Nat Rev Clin Oncol. 2012 May 8;9(6):314-26. doi: 10.1038/nrclinonc.2012.71. Nat Rev Clin Oncol. 2012. PMID: 22566105 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous